SCHEMBL3256605

SCHEMBL3256605

CN(CC=CC#CC(C)(C)CO)Cc1cccc2ccccc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.78
LMNA P02545 4/20 0.78
SLC6A2 P23975 3/20 0.78
SIGMAR1 Q99720 3/20 0.78
ADRA2A P08913 2/20 0.78
SQLE Q14534 1/20 0.78
KCNH2 Q12809 3/20 0.57
HIF1A Q16665 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP2C19 P33261 2/20 0.57
NR1I2 O75469 2/20 0.57
HTR2A P28223 2/20 0.57
SLC6A4 P31645 2/20 0.57
HTT P42858 2/20 0.57
DRD2 P14416 1/20 0.57
ADRA2C P18825 1/20 0.57
CNR1 P21554 1/20 0.57
ADRA1A P35348 1/20 0.57
OPRK1 P41145 1/20 0.57
SLC6A3 Q01959 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3256599 1.00 CYP2D6 (0.78) CYP2D6LMNASLC6A2SIGMAR1ADRA2A
SCHEMBL5087616 0.89 CYP2D6 (0.80) CYP2D6LMNASLC6A2SIGMAR1ADRA2A
SCHEMBL5087608 0.89 CYP2D6 (0.80) CYP2D6LMNASLC6A2SIGMAR1ADRA2A
SCHEMBL9633991 0.88 CYP2D6 (0.82) CYP2D6LMNASLC6A2SIGMAR1ADRA2A
SCHEMBL9633984 0.88 CYP2D6 (0.82) CYP2D6LMNASLC6A2SIGMAR1ADRA2A
Terbinafine SCHEMBL37843 0.88 CYP2D6 (1.00) CYP2D6LMNASLC6A2SIGMAR1ADRA2A
Terbinafine SCHEMBL2028187 0.88 CYP2D6 (1.00) CYP2D6LMNASLC6A2SIGMAR1ADRA2A
Terbinafine SCHEMBL2042785 0.88 CYP2D6 (1.00) CYP2D6LMNASLC6A2SIGMAR1ADRA2A
Terbinafine SCHEMBL5279646 0.88 CYP2D6 (1.00) CYP2D6LMNASLC6A2SIGMAR1ADRA2A
Terbinafine SCHEMBL36794 0.88 CYP2D6 (1.00) CYP2D6LMNASLC6A2SIGMAR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261874-B1 SPECIFIC MONOCLONAL ANTIBODY AGAINST TERBINAFINE NOVARTIS AG (CH) 2010-05-26 EP disclosed
US-7122184-B2 Specific monoclonal antibody against terbinafine NOVARTIS AG (CH) 2006-10-17 US disclosed
US-20030087323-A1 Specific monoclonal antibody against terbinafine NOVARTIS AG (CH) 2003-05-08 US disclosed
EP-1261874-A1 SPECIFIC MONOCLONAL ANTIBODY AGAINST TERBINAFINE Novartis AG (CH) 2002-12-04 EP disclosed
WO-2001059458-A1 SPECIFIC MONOCLONAL ANTIBODY AGAINST TERBINAFINE NOVARTIS AG (CH) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087323-A1 Specific monoclonal antibody against terbinafine NEFM, CD69, PBK CYP2D6 618/4885LMNA 3411/4885SLC6A2 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.